» Articles » PMID: 19004988

Altered Levels of Cytokines and Inflammatory Mediators in Plasma and Leukocytes of Sickle Cell Anemia Patients and Effects of Hydroxyurea Therapy

Overview
Journal J Leukoc Biol
Date 2008 Nov 14
PMID 19004988
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation, cell adhesion to vascular endothelium, and endothelial injury contribute to sickle cell anemia (SCA) vaso-occlusion. Although alterations in inflammatory cytokines and biomarkers have been related, reports have been conflicting, and a conclusive role for these molecules in the disease remains to be established. Furthermore, the effect of hydroxyurea therapy (HU) on the release of inflammatory mediators is not understood. This study aimed to determine plasma levels and leukocyte gene expressions of inflammatory mediators in healthy controls, steady-state SCA patients, and SCA patients on HU therapy. TNF-alpha, IL-8, and PGE(2) levels were significantly higher in the plasma of SCA individuals when compared with control individuals. HU therapy was associated with a significant reversal of augmented TNF-alpha and, interestingly, increased plasma anti-inflammatory IL-10. IFN-gamma, IL-10, cyclooxygenase 2 (COX-2), and inducible NO synthase (iNOS) gene expressions were unaltered in SCA mononuclear cells (MC); however, gene expressions of TNF-alpha, IL-8, and the protective enzyme heme oxygenase-1 (HO-1) were significantly higher. HU therapy was not associated with significantly altered SCA MC inflammatory gene expression, although COX-2 mRNA expression was decreased. In SCA neutrophils, gene expressions of IL-8, IFN-gamma, iNOS, and HO-1 were significantly higher than those of control subjects. Patients on HU demonstrated lower iNOS and higher IL-10 neutrophil gene expressions. Taken together, data suggest that alterations in the gene expressions and productions of a number of pro- and anti-inflammatory mediators are present in SCA and importantly, in those patients on HU therapy. Knowledge of these pathways may contribute to further the understanding of the pathophysiology of this disease.

Citing Articles

From early development to maturity: a phenotypic analysis of the Townes sickle cell disease mice.

Carol Illa A, Hvid H, Elm T, Frederiksen C, Bangshof L, Danielsen D Biol Open. 2025; 14(2).

PMID: 39912492 PMC: 11832121. DOI: 10.1242/bio.061828.


Sickle Cell Anemia and Inflammation: A Review of Stones and Landmarks Paving the Road in the Last 25 Years.

Dorneles J, de Menezes Mayer A, Chies J Hematol Rep. 2025; 17(1.

PMID: 39846606 PMC: 11755431. DOI: 10.3390/hematolrep17010002.


Inflammatory pathways and anti-inflammatory therapies in sickle cell disease.

Tozatto-Maio K, Ros F, Weinlich R, Rocha V Hemasphere. 2024; 8(12):e70032.

PMID: 39698332 PMC: 11655128. DOI: 10.1002/hem3.70032.


Role of endothelial dysfunction in sleep-disordered breathing in egyptian children with sickle cell disease.

Youssry I, Mostafa A, Hamed D, Hafez Y, Bishai I, Selim Y BMC Pediatr. 2024; 24(1):626.

PMID: 39354381 PMC: 11443814. DOI: 10.1186/s12887-024-05066-6.


Indicators for Osteomyelitis in Children With Sickle Cell Disease Admitted With Vaso-Occlusive Crises.

Tashkandi D, Hanafy E, Alotaibi N, Abuharfel D, Alnijaidi A, Banjar A Cureus. 2024; 16(8):e68265.

PMID: 39238724 PMC: 11375391. DOI: 10.7759/cureus.68265.